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To the Editor: In their recent assessment of 
Mycobacterium chimaera risk in patients undergo-
ing heart valve surgery, Sommerstein et al. com-
pare their findings to our prior risk assessment for 
UK patients (1,2). In their article, the authors note 
their assessed risk as “4 to 7” times higher than our 
risk estimate and suggest this relates to differences 
in case-finding methodology. Our study reported 
incidence density (cases per 10,000 person-years) 
to account for the differing lengths of postopera-
tive follow-up in each successive annual cohort of 
surgical patients. In contrast, Sommerstein et al. 
calculated crude risk based on annual procedure 
numbers. Since our published assessment was un-
dertaken some years before the authors’ assess-
ment, additional cases have been diagnosed, in 
keeping with the long incubation period for these 
infections, a median of 15 months but up to 5 years 
(3). Recalculation of risk and 95% (binomial) CIs, 
limited to 2008–2014 to match the authors’ assess-
ment, would yield a crude risk estimate of 0.24 
(0.15–0.35) per 1,000 procedures (24/102,234); the 
risk in Switzerland (11/14,054) would be estimated 
at 0.78 (0.39–1.40), just over 3 times higher.
Whether the observed differences between the 
United Kingdom and Switzerland represent a true 
difference in M. chimaera risk in patients undergo-
ing heart valve surgery is subject to debate. Both 
countries based case finding on results from rou-
tine diagnostic investigation; however, awareness 
of the risk in Switzerland predates that in other 
countries, potentially increasing the likelihood of 
investigation for mycobacterial infection. We have 
observed considerable variation in risk between 
cardiac centers, from 0 cases rising to 1 per 100 pa-
tients for 1 center in their year of highest estimated 
risk (4). Our pooled estimate covering 33 centers 
may encompass a wider selection of risk profiles, 
compared with the smaller number of centers in 
Switzerland.
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In Response: We would like to thank Lamagni et 
al. (1) for including additional cases from the period 
of 2008–2014 and for recalculating the UK cumulative 
incidence risk by matching our assessment. We agree 
that the observed 3 times higher risk in Switzerland 
of Mycobacterium chimaera infection for a patient un-
dergoing heart valve surgery cannot be explained un-
ambiguously. The most likely explanation is indeed 
increased awareness of the risk in Switzerland com-
pared with other countries, potentially improving 
likelihood of investigation for mycobacterial infec-
tion. We think that the early formation of a national 
and interdisciplinary working group (M. chimaera 
Task Force), which included representatives of the 
involved (para-)medical disciplines, authorities, and 
professional associations, has contributed greatly to 
raising this awareness.
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We want to emphasize that approximately half of 
the patients in Switzerland were treated for suspect-
ed sarcoidosis or other rheumatic diseases. It was via 
the active case finding mechanisms that these cases 
were identified. Furthermore, we would like to point 
out that, since the publication of our report (2), only 
one case known to the Task Force has been identi-
fied in Switzerland (in a patient whose surgery was 
performed in 2014). This finding could indicate that 
the formation of the national task force not only in-
creased awareness but also ensured that the remain-
ing infectious risk was reduced to a minimum within 
a very short time.
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Visit our website to listen:
https://tools.cdc.gov/ 
medialibrary/index.aspx#/ 
media/id/392605
EID Podcast: A Worm’s Eye View
Seeing a several-centimeters-long worm travers-
ing the conjunctiva of an eye is often the moment 
when many people realize they are infected with 
Loa loa, commonly called the African eyeworm, 
a parasitic nematode that migrates throughout 
the subcutaneous and connective tissues of in-
fected persons. Infection with this worm is called 
loiasis and is typically diagnosed either by the 
worm’s appearance in the eye or by a history of 
localized Calabar swellings, named for the coastal 
Nigerian town where that symptom was initially 
observed among infected persons. Endemic to a 
large region of the western and central African 
rainforests, the Loa loa microfilariae are passed 
to humans primarily from bites by flies from two 
species of the genus Chrysops, C. silacea and 
C. dimidiate. The more than 29 million people 
who live in affected areas of Central and West 
Africa are potentially at risk of loiasis. 
Ben Taylor, cover artist for the August 2018 issue 
of EID, discusses how his personal experience 
with the Loa loa parasite influenced this painting.
